✉ Email this page to a colleague
« Back to Dashboard
Capmatinib hydrochlorideis the generic ingredient in one branded drug marketed by Novartis Pharm and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.
Capmatinib hydrochloride has one hundred and seventy-four patent family members in forty-four countries.
One supplier is listed for this compound.
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for capmatinib hydrochloride
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for capmatinib hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
|Yonsei University||Phase 2|
|Southwest Oncology Group||Phase 2|
|National Cancer Institute (NCI)||Phase 2|
Pharmacology for capmatinib hydrochloride
|Country||Patent Number||Title||Estimated Expiration|
|South Korea||101532256||⤷ Try a Trial|
|Japan||6105653||⤷ Try a Trial|
|Hungary||E053346||⤷ Try a Trial|
|Argentina||111428||SALES DE 2-FLUORO-N-METIL-4-[7-(QUINOLIN-6-IL-METIL)-IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-IL]BENZAMIDA Y PROCESOS RELACIONADOS CON LA PREPARACIÓN DE LAS MISMAS||⤷ Try a Trial|
|Serbia||52677||IMIDAZOTRIAZINI I IMIDAZOPIRIMIDINI KAO INHIBITORI KINAZE (IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS)||⤷ Try a Trial|
|Portugal||3034075||⤷ Try a Trial|
|>Country||>Patent Number||>Title||>Estimated Expiration|
|Patent Number||Supplementary Protection Certificate||SPC Country||SPC Expiration||SPC Description|
|2099447||53/2022||Austria||⤷ Try a Trial||PRODUCT NAME: CAPMATINIB ODER EIN PHARMAZEUTISCH UNBEDENKLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/22/1650 (MITTEILUNG) 20220621|
|3172209||51/2022||Austria||⤷ Try a Trial||PRODUCT NAME: CAPMATINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/22/1650 (MITTEILUNG) 20220621|
|3172209||122022000076||Germany||⤷ Try a Trial||PRODUCT NAME: CAPMATINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/22/1650 20220620|
|3172209||CA 2022 00056||Denmark||⤷ Try a Trial||PRODUCT NAME: CAPMATINIB ELER ET FARMACEUTISK ACCEPTABLET SALT DERAF; REG. NO/DATE: EU/1/22/1650 20220621|
|2099447||CA 2022 00053||Denmark||⤷ Try a Trial||PRODUCT NAME: CAPMATINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/22/1650 20220621|
|2099447||301209||Netherlands||⤷ Try a Trial||PRODUCT NAME: CAPMATINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/22/1650 20220621|
|>Patent Number||>Supplementary Protection Certificate||>SPC Country||>SPC Expiration||>SPC Description|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.